Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

BACKGROUND: Cangrelor is an intravenous P2Y(12) inhibitor approved to reduce periprocedural ischemic events in patients undergoing percutaneous coronary intervention not pretreated with a P2Y(12) inhibitor. METHODS: A total of 11 145 patients were randomized to cangrelor or clopidogrel in the CHAMPI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circulation
Main Authors: Cavender, Matthew A., Bhatt, Deepak L., Stone, Gregg W., White, Harvey D., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Leonardi, Sergio, Prats, Jayne, Deliargyris, Efthymios N., Mahaffey, Kenneth W., Harrington, Robert A.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2016
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006794/
https://ncbi.nlm.nih.gov/pubmed/27482008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.115.020829
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados